Vorinostat and bortezomib significantly inhibit WT1 gene expression in MO7-e and P39 cell lines [1]

Leukemia

Volumn 22, Issue 3, 2008, Pages 628-631

  Galimberti, S ^a   Canestraro, M ^a   Khan, R ^b   Buda, G ^a   Orciuolo, E ^a   Guerrini, F ^a   Fazzi, R ^a   Maffei, R ^c   Marasca, R ^c   Petrini, M ^a  

^a UNIVERSITY OF PISA   (Italy)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; VORINOSTAT; WT1 PROTEIN;

ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CELL VIABILITY; CONCENTRATION RESPONSE; CYTOTOXICITY; DOWN REGULATION; DRUG EFFICACY; DRUG POTENTIATION; GENE EXPRESSION; HUMAN; IC 50; INCUBATION TIME; LETTER; LEUKEMIA CELL LINE; PRIORITY JOURNAL;

EID: 40749118898     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404918     Document Type: Letter

References (8)

1. Yang L, Han Y, Saurez Saiz F, Minden MD. A tumor suppressor and oncogene: The WT1 story. Leukemia 2007; 21: 868-876.
2. Dehbi M, Hiscott J, Pelletier J. Activation of the WT1 Wilms' tumor suppressor gene by NF-kappaB. Oncogene 1998; 16: 2033-2039.
3. Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applicatioos. Blood 2003; 101: 2377-2380.
4. Takada Y, Gillenwater A, Ichikawa H, Aggarwal BB. Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation. J Biol Chem 2006; 281: 5612-5622.
5. Fazzi R, Pacini S, Testi R, Azzarà A, Galimberti S, Testi C et al Carboxy-terminal fragment of osteogeneic growth peptide in vitro increases bone marrow cell density in idiopathic myelofibrosis. Br J Haematol 2003; 121: 76-85.
6. Khan R, Aggerholm A, Hokland P, Hassan M, Hellström-Lindberg,E. A pharmacodynamic study of 5-azacytidine in the P39 cell line. Exp Hematol 2006; 34: 35-43.
7. Galimberti S, Guerrini F, Carulli G, Fazzi R, Palumbo GA, Morabito F et al. Significant co-expression of WT1 and MDR1 genes in acute myeloid leukemia patients at diagnosis. Eur J Haematol 2004; 72 45-51.
8. Sutheesophon K, Kobayashi Y, Takatoku MA, Ozawa K, Kano Y, Ishii H et al. Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib. Acta Haematol 2006; 115: 78-90.